Saturday, August 13, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

AGA recommends early use of biologics in patients with moderate-to-severe Crohn’s disease

May 27, 2021
in Medicine & Health
0
Share on FacebookShare on Twitter

The American Gastroenterological Association (AGA) issues new clinical guidelines on drug therapy for the management of moderate-to-severe luminal and fistulizing Crohn’s disease.

IMAGE

Credit: American Gastroenterological Association

Bethesda, MD (May 27, 2021) — Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations and surgery when not adequately controlled. While there is no cure for Crohn’s disease, there are treatments that can help patients live a symptom-free life.

After a detailed review of available literature, the American Gastroenterological Association (AGA) has released new clinical guidelines outlining the benefits and risks of each drug currently available to Crohn’s patients. Based on this research, AGA recommends the early introduction of biologics for patients experiencing luminal and fistulizing Crohn’s disease rather than waiting until other treatments fail. These guidelines are published in Gastroenterology, AGA’s official journal.

“With many new drugs entering the market, clinician’s ability to treat patients with Crohn’s disease has improved greatly over the last 20 years,” said lead author Joseph D. Feuerstein, MD, from Beth Israel Deaconess, Boston, Massachusetts. “We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery.”

Key guideline recommendations:

    1. Biologics are the most effective drugs for the management of Crohn’s and they should be used early, rather than delaying their use until after failure of mesalamine and/or corticosteroids, in patients with moderate to severe or fistulizing Crohn’s disease. These drugs are antibodies and can more precisely target the immune system which is causing the inflammation in Crohn’s disease.

    a. Anti-tumor necrosis factor (anti-TNF) agents or ustekinumab are recommended and vedolizumab is suggested as a first-line treatment.

    b. In patients who have previously not responded to anti-TNF agents, AGA recommends ustekinumab or vedolizumab.

    c. The biologic natalizumab is no longer recommended due to potential adverse events and the availability of safer treatment options.

Read the AGA Clinical Practice Guideline on the Medical Management of Moderate to Severe Luminal and Fistulizing Crohn’s Disease to review all 25 recommendations.

###

Resources

Guidelines

Technical review

Spotlight (infographic)

Clinical Decision Support Tool

Commentary: Providing the Best Care for Patients with Crohn’s Disease: An Examination of the New AGA Clinical Practice Guideline on the Medical Management of Moderate to Severe Luminal and Fistulizing Crohn’s Disease

Media contact: Courtney Reed, [email protected], 301-272-0025

About the AGA Institute

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org.

AGA is now on Instagram.

Like AGA on Facebook.

Follow us on Twitter @AmerGastroAssn.

Check out our videos on YouTube.

Join AGA on LinkedIn.

Media Contact
Courtney Reed
[email protected]

Tags: GastroenterologyInternal MedicineLiverMedicine/Health
Share25Tweet16Share4ShareSendShare
  • Amanda Poholek, Ph.D.

    Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

    122 shares
    Share 49 Tweet 31
  • A new method boosts wind farms’ energy output, without new equipment

    75 shares
    Share 30 Tweet 19
  • Researchers fabricate cobalt copper catalysts for methane on metal-organic framework Contributes to goal of methane production from carbon dioxide emissions

    67 shares
    Share 27 Tweet 17
  • New insights on how some individuals with obesity can lose weight – and keep it off

    66 shares
    Share 26 Tweet 17
  • Brightest stars in the night sky can strip Neptune-sized planets to their rocky cores

    65 shares
    Share 26 Tweet 16
  • The North American Menopause Society releases its 2022 Hormone Therapy Position Statement

    145 shares
    Share 58 Tweet 36
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Reinvigorating ‘lost cause’ exhausted T cells could improve cancer immunotherapy

Experts optimistic about converting coal plants to production of clean geothermal energy

A role for cell ‘antennae’ in managing dopamine signals in the brain

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 193 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In